ActoGeniX: 20 million euros round


Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.



Brussels – For the first time, researchers from Vrije Universiteit Brussels, VIB and Stanford University have frozen adrenaline binding to its hyperdynamic receptor for structural analysis (Nature,doi:10.1038/nature09648). The...



Hilden/Berlin – Qiagen NV has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a pioneer in the field of deep sequencing based therapy guidance, clinical trial stratification, and ...



Mechelen – Genomics and drug discovery services company Galapagos NV, has triggered another milestone payment in its alliance with Janssen Pharmaceutica NV in the field of rheumatoid arthritis, receiving a milestone payment of...



Mechelen – Belgian service and drug development specialist Galapagos NV has raised EUR28.7m through the sale of 2.4 million shares at a 12 per share in a private placement. The share price represents an 8 % discount to Galapagos’...



Brussels – The animal welfare group “Four Paws” has called on the European Commission to stop considering postponement of the ban to end animal testing for cosmetics. According to Directive 76/768/EEC animal tests for...



Brussels – New draft legislation from the European Commission proposes a ban in the bloc on marketing foods from cloned animals for the next five years. Health Commissioner John Dalli said that the new rules are not based on food...



Brussels – Biopharma giant UCB Group has secured exclusive rights to two drug candidates for treating Parkinson’s disease from Swiss drug developer Synosia Therapeutics AG. Synosia will receive an undisclosed upfront payment and...

Displaying results 61 to 70 out of 304

< Previous 61-70 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • WILEX4.84 EUR34.82%
  • FORMYCON31.25 EUR11.61%
  • PAION2.76 EUR6.98%


  • MEDIGENE12.41 EUR-3.42%
  • SANTHERA96.75 CHF-2.12%
  • MOLOGEN5.01 EUR-1.18%


  • WILEX4.84 EUR63.5%
  • FORMYCON31.25 EUR35.0%
  • CO.DON3.35 EUR29.8%


  • CYTOS1.08 CHF-22.9%
  • BIOTEST78.40 EUR-18.9%
  • THERAMETRICS0.07 CHF-12.5%


  • SANTHERA96.75 CHF2368.1%
  • CYTOS1.08 CHF671.4%
  • WILEX4.84 EUR469.4%


  • MOLOGEN5.01 EUR-55.5%
  • BIOFRONTERA2.40 EUR-26.8%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.04.2015

Current issue

All issues